Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Cipla Ltd ( (IN:CIPLA) ) is now available.
Cipla Ltd’s board has approved the audited standalone and consolidated financial results for the quarter and full year ended 31 March 2026, accompanied by an unmodified auditor’s opinion and a confirmation from the Global Chief Financial Officer. These filings, made under SEBI listing norms, signal clean financial reporting and are accessible to investors through the company’s website.
Alongside the results, the board has recommended a final dividend of Rs 13 per equity share for FY 2025-26, with a record date of 5 June 2026 and payment to follow within 30 days of shareholder approval at the upcoming AGM. The payout underlines Cipla’s continued focus on shareholder returns and may be viewed positively by investors tracking the company’s capital allocation and cash-generation profile.
More about Cipla Ltd
Cipla Ltd is a leading Indian pharmaceutical company headquartered in Mumbai, focused on manufacturing and marketing generic medicines and active pharmaceutical ingredients across global markets. The company operates through standalone and consolidated businesses, with its shares listed on Indian exchanges and debt instruments listed in Luxembourg, reflecting a broad-based investor base.
Average Trading Volume: 104,364
Technical Sentiment Signal: Hold
Current Market Cap: 1043.7B INR
For detailed information about CIPLA stock, go to TipRanks’ Stock Analysis page.